Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations
Over the last decade, new therapeutics in the form of anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition have offered new options for the treatment of ovarian cancer. This review summarizes studies related to these treatment modalities and additionally novel combinations that...
Main Authors: | Marisa C Liu, Krishnansu S Tewari |
---|---|
Format: | Article |
Language: | English |
Published: |
BioExcel Publishing Ltd
2018-12-01
|
Series: | Drugs in Context |
Subjects: | |
Online Access: | https://www.drugsincontext.com/antiangiogenesis-therapy-synthetic-lethality-and-checkpoint-inhibition-in-ovarian-cancer |
Similar Items
-
First-line treatment of advanced ovarian cancer: an expert update
by: Branka Petrić-Miše
Published: (2020-01-01) -
Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer
by: Tadahiro Shoji, et al.
Published: (2021-05-01) -
The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
by: Margherita Turinetto, et al.
Published: (2021-06-01) -
Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives
by: Brigida Anna Maiorano, et al.
Published: (2021-09-01) -
PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality—An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness
by: Patrycja Gralewska, et al.
Published: (2020-12-01)